HomeTrialNCT06178614
🔬NCT06178614Phase 1RECRUITING

A Study of JNJ-87890387 for Advanced Solid Tumors

Study Summary

The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment200 participants
Primary Completion
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550949+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.